13 research outputs found
Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients
Lymphopenia has been consistently reported as associated with severe coronavirus disease
2019 (COVID-19). Several studies have described a profound decline in all T-cell subtypes in hospitalized patients with severe and critical COVID-19. The aim of this study was to assess the role of
T-lymphocyte subset absolute counts measured at ward admission in predicting 30-day mortality in
COVID-19 hospitalized patients, validating a new prognostic score, the T-Lymphocyte Subset Index
(TLSI, range 0–2), based on the number of T-cell subset (CD4+ and CD8+) absolute counts that are below prespecified cutoffs. These cutoff values derive from a previously published work of our research
group at Policlinico Tor Vergata, Rome, Italy: CD3+CD4+ < 369 cells/µL, CD3+CD8+ < 194 cells/µL.
In the present single-center retrospective study, T-cell subsets were assessed on admission to the
infectious diseases ward. Statistical analysis was performed using JASP (Version 0.16.2. JASP Team,
2022, The Amsterdam, The Netherlands) and Prism8 (version 8.2.1. GraphPad Software, San Diego,
CA, USA). Clinical and laboratory parameters of 296 adult patients hospitalized because of COVID-19
were analyzed. The overall mortality rate was 22.3% (66/296). Survivors (S) had a statistically
significant lower TLSI score compared to non-survivors (NS) (p < 0.001). Patients with increasing
TLSI scores had proportionally higher rates of 30-day mortality (p < 0.0001). In the multivariable
logistic analysis, the TLSI was an independent predictor of in-hospital 30-day mortality (OR: 1.893,
p = 0.003). Survival analysis showed that patients with a TLSI > 0 had an increased risk of death
compared to patients with a TLSI = 0 (hazard ratio: 2.83, p < 0.0001). The TLSI was confirmed as an
early and independent predictor of COVID-19 in-hospital 30-day mortalit
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study
Background Since its outbreak in early 2020, the COVID-19 pandemic has diverted resources from non-urgent and elective procedures, leading to diagnosis and treatment delays, with an increased number of neoplasms at advanced stages worldwide. The aims of this study were to quantify the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic; and to evaluate whether delays in surgery led to an increased occurrence of aggressive tumours.Methods In this retrospective, international, cross-sectional study, centres were invited to participate in June 22, 2022; each centre joining the study was asked to provide data from medical records on all surgical thyroidectomies consecutively performed from Jan 1, 2019, to Dec 31, 2021. Patients with indeterminate thyroid nodules were divided into three groups according to when they underwent surgery: from Jan 1, 2019, to Feb 29, 2020 (global prepandemic phase), from March 1, 2020, to May 31, 2021 (pandemic escalation phase), and from June 1 to Dec 31, 2021 (pandemic decrease phase). The main outcomes were, for each phase, the number of surgeries for indeterminate thyroid nodules, and in patients with a postoperative diagnosis of thyroid cancers, the occurrence of tumours larger than 10 mm, extrathyroidal extension, lymph node metastases, vascular invasion, distant metastases, and tumours at high risk of structural disease recurrence. Univariate analysis was used to compare the probability of aggressive thyroid features between the first and third study phases. The study was registered on ClinicalTrials.gov, NCT05178186.Findings Data from 157 centres (n=49 countries) on 87 467 patients who underwent surgery for benign and malignant thyroid disease were collected, of whom 22 974 patients (18 052 [78 center dot 6%] female patients and 4922 [21 center dot 4%] male patients) received surgery for indeterminate thyroid nodules. We observed a significant reduction in surgery for indeterminate thyroid nodules during the pandemic escalation phase (median monthly surgeries per centre, 1 center dot 4 [IQR 0 center dot 6-3 center dot 4]) compared with the prepandemic phase (2 center dot 0 [0 center dot 9-3 center dot 7]; p<0 center dot 0001) and pandemic decrease phase (2 center dot 3 [1 center dot 0-5 center dot 0]; p<0 center dot 0001). Compared with the prepandemic phase, in the pandemic decrease phase we observed an increased occurrence of thyroid tumours larger than 10 mm (2554 [69 center dot 0%] of 3704 vs 1515 [71 center dot 5%] of 2119; OR 1 center dot 1 [95% CI 1 center dot 0-1 center dot 3]; p=0 center dot 042), lymph node metastases (343 [9 center dot 3%] vs 264 [12 center dot 5%]; OR 1 center dot 4 [1 center dot 2-1 center dot 7]; p=0 center dot 0001), and tumours at high risk of structural disease recurrence (203 [5 center dot 7%] of 3584 vs 155 [7 center dot 7%] of 2006; OR 1 center dot 4 [1 center dot 1-1 center dot 7]; p=0 center dot 0039).Interpretation Our study suggests that the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic period could have led to an increased occurrence of aggressive thyroid tumours. However, other compelling hypotheses, including increased selection of patients with aggressive malignancies during this period, should be considered. We suggest that surgery for indeterminate thyroid nodules should no longer be postponed even in future instances of pandemic escalation.Funding None.Copyright (c) 2023 Published by Elsevier Ltd. All rights reserved
Il machine learning e i big data a supporto della contabilitĂ degli enti pubblici: il caso del sistema di ristorazione universitario
Questa tesi si propone di integrare le più recenti tecnologie atte alla raccolta, analisi e interpretazione dei big data nel contesto del controllo di gestione dell'azienda regionale per il diritto allo studio universitario. In particolare, il seguente lavoro si concentra sull'utilizzo dei metadati estratti dal database del sistema di ristorazione erogato nella città di Pisa, al fine di automatizzare la generazione di indici consuntivi e sviluppare analisi predittive attraverso l'applicazione di tecniche di machine learning. L'obbiettivo è indagare come queste metodologie all'avanguardia possano essere applicate nell'analisi contabile di un ente pubblico per valutare l'efficienza ed efficacia del servizio fornito
BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer
Background. Molecular diagnostics has offered new techniques for searching for mutations in thyroid indeterminate lesions. The study’s aim was to evaluate the BRAF mutations’ incidence in an Italian regional population. Subjects and Methods. 70 Caucasian patients born in Liguria with indeterminate or suspicious cytological diagnoses. Results. A BRAF gene mutation was successfully analyzed in 56/70 patients. The mutation was BRAF V600E in 12/56 cases (21%) and BRAF K601E in 2/56 (4%). Of the BRAF mutated samples on cytological diagnosis (14/56 cases), 2/14 cases (14%) were benign on final histology and 12/14 (86%) were malignant. All BRAF-mutated cases on cytology that were found to be benign on histological examination carried the K601E mutation. Of the nonmutated BRAF cases (42/56, 75%) which were later found to be malignant on definitive histology, 5 cases were follicular carcinomas (36%), 3 cases were incidentally found to be papillary microcarcinomas (22%), 2 were cases papillary carcinomas (14%), 1 was case follicular variant of papillary carcinoma (7%), 1 was case medullary carcinoma (7%), 1 case was Hurtle cell tumor (7%), and 1 case was combined cell carcinoma and papillary oncocytic carcinoma (7%). Conclusions. The presence of the BRAF V600E mutation may suggest a more aggressive surgical approach. BRAF K601E mutation did not correlate with malignancy indexes
BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer
Background. Molecular diagnostics has offered new techniques for searching for mutations in thyroid indeterminate lesions. The study's aim was to evaluate the BRAF mutations' incidence in an Italian regional population. Subjects and Methods. 70 Caucasian patients born in Liguria with indeterminate or suspicious cytological diagnoses. Results. A BRAF gene mutation was successfully analyzed in 56/70 patients. The mutation was BRAF V600E in 12/56 cases (21%) and BRAF K601E in 2/56 (4%). Of the BRAF mutated samples on cytological diagnosis (14/56 cases), 2/14 cases (14%) were benign on final histology and 12/14 (86%) were malignant. All BRAF-mutated cases on cytology that were found to be benign on histological examination carried the K601E mutation. Of the nonmutated BRAF cases (42/56, 75%) which were later found to be malignant on definitive histology, 5 cases were follicular carcinomas (36%), 3 cases were incidentally found to be papillary microcarcinomas (22%), 2 were cases papillary carcinomas (14%), 1 was case follicular variant of papillary carcinoma (7%), 1 was case medullary carcinoma (7%), 1 case was Hurtle cell tumor (7%), and 1 case was combined cell carcinoma and papillary oncocytic carcinoma (7%). Conclusions. The presence of the BRAF V600E mutation may suggest a more aggressive surgical approach. BRAF K601E mutation did not correlate with malignancy indexes
Admission eGFR predicts in-hospital mortality independently of admission glycemia and C-peptide in patients with type 2 diabetes mellitus and COVID-19
ABSTRACT
Objective: Type 2 diabetes mellitus (T2DM) and impaired kidney function are associated with a higher
risk of poor outcomes of coronavirus disease 2019 (COVID-19). We conducted a retrospective study in
hospitalized T2DM patients with COVID-19 to assess the association between in-hospital mortality and
admission values of different hematological/biochemical parameters, including estimated glomerular filtration
rate (eGFR), plasma glucose and C-peptide (the latter serving as a marker of beta-cell function).
Methods: The study included T2DM patients with confirmed severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection who were consecutively admitted to our Institution between 1
October 2020 and 1 April 2021.
Results: Patients (nÂĽ74) were categorized into survivors (nÂĽ55) and non-survivors (nÂĽ19). Nonsurvivors
exhibited significantly higher median white blood cell (WBC) count, D-dimer, neutrophil-tolymphocyte
ratio, high-sensitivity C-reactive protein (hsCRP), and procalcitonin levels, as well as significantly
lower median serum 25-hydroxyvitamin D [25(OH)D] levels compared to survivors. Non-survivors
exhibited significantly higher median admission plasma glucose (APG) values compared to survivors (210
vs. 166mg/dL; pÂĽ.026). There was no statistically significant difference in median values of (random)
plasma C-peptide between non-survivors and survivors (3.55 vs. 3.24 ng/mL; pÂĽ.906). A significantly
higher percentage of patients with an eGFR < 60mL/min/1.73 m2 was observed in the non-survivor
group as compared to the survivor group (57.9% vs. 23.6%; pÂĽ.006). A multivariate analysis performed
by a logistic regression model after adjusting for major confounders (age, sex, body mass index, major
comorbidities) showed a significant inverse association between admission eGFR values and risk of in-hospital
mortality (OR, 0.956; 95% CI, 0.931-0.983; pÂĽ.001). We also found a significant positive association
between admission WBC count and risk of in-hospital mortality (OR, 1.210; 95% CI, 1.043–1.404; p¼.011).
Conclusions: Admission eGFR and WBC count predict in-hospital COVID-19 mortality among T2DM
patients, independently of traditional risk factors, APG and random plasma C-peptide. Hospitalized
patients with COVID-19 and comorbid T2DM associated with impaired kidney function at admission
should be considered at high risk for adverse outcomes and death
Frequency of Atypical Mutations in the Spike Glycoprotein in SARS-CoV-2 Circulating from July 2020 to July 2022 in Central Italy: A Refined Analysis by Next Generation Sequencing
In this study, we provided a retrospective overview in order to better define SARS-CoV-2 variants circulating in Italy during the first two years of the pandemic, by characterizing the spike mutational profiles and their association with viral load (expressed as ct values), N-glycosylation pattern, hospitalization and vaccination. Next-generation sequencing (NGS) data were obtained from 607 individuals (among them, 298 vaccinated and/or 199 hospitalized). Different rates of hospitalization were observed over time and among variants of concern (VOCs), both in the overall population and in vaccinated individuals (Alpha: 40.7% and 31.3%, Beta: 0%, Gamma: 36.5% and 44.4%, Delta: 37.8% and 40.2% and Omicron: 11.2% and 7.1%, respectively, both p-values 90%), with a distribution differing among the strains (22.9% in Alpha, 14.3% in Beta, 41.8% in Gamma, 46.5% in Delta and 15.4% in Omicron, p-value < 0.001). Overall, significantly less atypical variability was observed in vaccinated individuals than unvaccinated individuals; nevertheless, vaccinated people who needed hospitalization showed an increase in atypical variability compared to vaccinated people that did not need hospitalization. Only 5/607 samples showed a different putative N-glycosylation pattern, four within the Delta VOC and one within the Omicron BA.2.52 sublineage. Interestingly, atypical minor mutations (intra-prevalence < 20%) were associated with higher Ct values and a longer duration of infection. Our study reports updated information on the temporal circulation of SARS-CoV-2 variants circulating in Central Italy and their association with hospitalization and vaccination. The results underline how SARS-CoV-2 has changed over time and how the vaccination strategy has contributed to reducing severity and hospitalization for this infection in Italy
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
Background: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS).Objectives: to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment.Methods: Case series.Results: Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae.Conclusion: Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection